Trial Profile
RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RETRAP
- 15 Oct 2016 Status changed from recruiting to completed.
- 27 May 2014 New trial record